Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Solubility of water in perfluorodimethylcyclohexanes as a function of temperature /

Work performed at the Carbide and Carbon Chemicals Corporation, K-25 Laboratory Division."Date Declassified: October 13, 1948.""AECD-2337."Includes bibliographical references (p. 6).Mode of access: Internet